Longeveron (LGVN) Accounts Payables (2022 - 2026)
Longeveron (LGVN) posted quarterly Accounts Payables of $293000.0 for Q1 2026, down 20.16% year-over-year from $367000.0 in Q1 2025, and down 30.73% quarter-over-quarter from $423000.0 in Q4 2025.
Longeveron (LGVN) Accounts Payables (2022 - 2026) Analysis & Trends
Longeveron's Accounts Payables history runs 5 years deep, the most recent figure standing at $293000.0 for Q1 2026.
- In Q1 2026, Accounts Payables fell 20.16% year-over-year to $293000.0; the TTM figure through Mar 2026 stood at $293000.0 (down 20.16% YoY), while the FY2025 annual figure was $423000.0, up 327.27% from the prior year.
- Accounts Payables for Q1 2026 stood at $293000.0, down from $423000.0 in the prior quarter.
- The five-year high for Accounts Payables was $1.8 million in Q4 2022, with the low at $99000.0 in Q4 2024.
- The 5-year median for Accounts Payables is $669000.0 (2023), against an average of $833750.0.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 84.48% in 2024, then soared 327.27% in 2025.
- Longeveron's Accounts Payables stood at $1.8 million in 2022, then sank by 63.56% to $638000.0 in 2023, then slumped by 84.48% to $99000.0 in 2024, then jumped by 327.27% to $423000.0 in 2025, then plunged by 30.73% to $293000.0 in 2026.
- Business Quant data shows LGVN's Accounts Payables at $293000.0 in Q1 2026, $423000.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 633,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 633,000.00 |
| Mar 31, 2026 | 293,000.00 |
| Dec 31, 2025 | 423,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 367,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | 887,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 638,000.00 |
| Jun 30, 2023 | 1.70 Mn |
| Dec 31, 2022 | 1.75 Mn |